Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2NO3.Ni |
Molecular Weight | 182.7032 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ni++].[O-][N+]([O-])=O.[O-][N+]([O-])=O
InChI
InChIKey=KBJMLQFLOWQJNF-UHFFFAOYSA-N
InChI=1S/2NO3.Ni/c2*2-1(3)4;/q2*-1;+2
DescriptionSources: https://www.nicnas.gov.au/chemical-information/imap-assessments/imap-group-assessment-report?assessment_id=883http://onlinelibrary.wiley.com/doi/10.1002/14356007.a17_235.pub2/abstractCurator's Comment: description was created based on several sources, including
https://www.cdc.gov/niosh/docs/81-123/pdfs/0445.pdf
Sources: https://www.nicnas.gov.au/chemical-information/imap-assessments/imap-group-assessment-report?assessment_id=883http://onlinelibrary.wiley.com/doi/10.1002/14356007.a17_235.pub2/abstract
Curator's Comment: description was created based on several sources, including
https://www.cdc.gov/niosh/docs/81-123/pdfs/0445.pdf
Nickel nitrate is the inorganic compound Ni(NO3)2. The most common form of nickel nitrate is hexahydrate. It is irritating to the eyes, skin and, upon inhalation of the dust, respiratory tract. It may cause skin allergy. Along with most other nickel compounds, nickel nitrate is a carcinogen. Nickel(II) nitrate hexahydrate is widely used in the production of nickel catalysts, by impregnating an inert carrier and decomposing the nitrate.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7577320
Curator's Comment: The Ni compounds used in this experiment were nickel metal [Ni-M], nickel oxide (green) [NiO(G)], nickel oxide (black) [NiO(B)], nickel subsulfide [Ni3S2], nickel sulfide [NiS], nickel sulfate [NiSO4], nickel chloride [NiCl2], and nickel nitrate [Ni(NO3)2]. The solubilities of the nickel compounds in saline solution were in the following order; [Ni(NO3)2 > NiCl2 > NiSO4] >> [NiS > Ni3S2] > [NiO(B) > Ni-M > NiO(G)]. The Ni level in the visceral organs was higher in the rats given soluble Ni compounds; Ni(NO3)2, NiCl2, NiSO4, than that in the rats receiving other compounds. In the rats to which soluble Ni compounds were administered, 80-90% of the recovered Ni amounts in the examined organs was detected in the kidneys.
Distribution of various nickel compounds in rat organs
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11802473
Human stratum corneum (SC) was prepared by trypsinization of dermatomed cadaver leg skin. The diffusion system included diffusion cells with a spiral line. Aqueous solutions of nickel salts (Ni(NO3)2, NiSO4, NiCl2 and Ni(-OOCCH3)2 at 1% Ni2+ concentration) were used as the donor solution (400 microL/cell). The receptor fluid, pure water, was collected up to 96 h after application of the donor solutions. Nickel concentrations in the donor and receptor fluid, as well as in the SC, were analysed using inductively coupled plasma mass spectrometry (ICP-MS) with a confidence limit of 0.5 ppb. Based on the total recovery of nickel from the experiments, about 98% of the dose remained in the donor solution, whereas 1% or less was retained in SC and less than 1% was found in the receptor fluid. Following an early surge, nickel permeates slowly across SC. The steady-state permeability coefficients of nickel were calculated from the flux data (approximately 5.2-8.5 x 10(-7) cm/h) with no significant difference among the salts. The results concur in principle with earlier studies conducted using the full-thickness human skin in vitro, and suggest that in vivo nickel ions may permeate simultaneously by routes of diffusion such as the shunt pathway, apart from slow transcellular/intercellular diffusion alone.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID70872958
Created by
admin on Fri Dec 15 17:59:58 GMT 2023 , Edited by admin on Fri Dec 15 17:59:58 GMT 2023
|
PRIMARY | |||
|
236-068-5
Created by
admin on Fri Dec 15 17:59:58 GMT 2023 , Edited by admin on Fri Dec 15 17:59:58 GMT 2023
|
PRIMARY | |||
|
C035197
Created by
admin on Fri Dec 15 17:59:58 GMT 2023 , Edited by admin on Fri Dec 15 17:59:58 GMT 2023
|
PRIMARY | |||
|
25736
Created by
admin on Fri Dec 15 17:59:58 GMT 2023 , Edited by admin on Fri Dec 15 17:59:58 GMT 2023
|
PRIMARY | |||
|
NICKEL(II) NITRATE
Created by
admin on Fri Dec 15 17:59:58 GMT 2023 , Edited by admin on Fri Dec 15 17:59:58 GMT 2023
|
PRIMARY | |||
|
13138-45-9
Created by
admin on Fri Dec 15 17:59:58 GMT 2023 , Edited by admin on Fri Dec 15 17:59:58 GMT 2023
|
PRIMARY | |||
|
m7868
Created by
admin on Fri Dec 15 17:59:58 GMT 2023 , Edited by admin on Fri Dec 15 17:59:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
1829
Created by
admin on Fri Dec 15 17:59:58 GMT 2023 , Edited by admin on Fri Dec 15 17:59:58 GMT 2023
|
PRIMARY | |||
|
50L0S38I2D
Created by
admin on Fri Dec 15 17:59:58 GMT 2023 , Edited by admin on Fri Dec 15 17:59:58 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD